Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Gets Europe OK for Zeposia in Ulcerative Colitis

11/23/2021 | 07:29am EST

By Colin Kellaher

Bristol Myers Squibb Co. on Tuesday said the European Commission approved the expanded use of its multiple-sclerosis drug Zeposia for the treatment of adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease.

The New York biopharmaceutical company said the approval covers patients who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Bristol Myers last year received U.S. and European approval for Zeposia in adults with relapsing forms of multiple sclerosis and earlier this year received U.S. Food and Drug Administration approval for the drug ulcerative colitis. The company is also evaluating the drug as a treatment for Crohn's disease.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

11-23-21 0729ET

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -0.06% 64.89 Delayed Quote.4.07%
CORN FUTURES (C) - CBR (FLOOR)/C1 0.55% 599.5 End-of-day quote.0.51%
All news about BRISTOL-MYERS SQUIBB COMPANY
01/11Evotec, Bristol Myers Expand Neurogenerative Partnership to Include New Targeted Protei..
MT
01/11Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination ..
AQ
01/11Evogene's Biomica Gets Israeli Nod To Move Ahead With Cancer Trial
MT
01/10BioAlta, Bristol Myers Squibb Partnering on Potential Cancer Treatments
MT
01/10BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab ..
PR
01/10Bioatla, Inc. Enters into a Clinical Collaboration with Bristol Myers Squibb to Investi..
CI
01/10Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement
MT
01/10Century Therapeutics Shares Rise 12% Premarket After Bristol Myers Deal
DJ
01/10BRISTOL MYERS SQUIBB : JP Morgan Presentation
PU
01/10BRISTOL MYERS SQUIBB CO : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 405 M - -
Net income 2021 6 271 M - -
Net Debt 2021 28 505 M - -
P/E ratio 2021 21,9x
Yield 2021 3,03%
Capitalization 144 B 144 B -
EV / Sales 2021 3,72x
EV / Sales 2022 3,41x
Nbr of Employees 30 250
Free-Float -
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 64,89 $
Average target price 71,79 $
Spread / Average Target 10,6%
EPS Revisions
Managers and Directors
Giovanni Caforio Senior Vice President-US Oncology
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY4.07%144 033
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992